

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

VOLUNTARY ANNOUNCEMENT SETTLEMENT OF DISPUTES

The board (the “**Board**”) of directors (the “**Directors**”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries the “**Group**”) announces that on December 16, 2025, the Company has entered into a settlement agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“**MediLink Therapeutics**”), Dr. Xue Tongtong, Dr. Xiao Liang and Dr. Jia Qiang Cai (the “**Individuals**” and collectively, the “**MediLink Parties**”), to settle certain disputes initiated and/or commenced by the Company against the MediLink Parties (the “**Settlement**”).

BACKGROUND

The Company (1) filed a criminal case in 2024 and commenced a civil litigation against the MediLink Parties for alleged misappropriation of trade secrets in 2025; and (2) commenced another civil litigation against the MediLink Parties for allegedly causing detriment to the Company's interests in 2025 (collectively, the “**Legal Proceedings**”).

THE SETTLEMENT

In order to save time and costs in connection with the Legal Proceedings, the Company and the MediLink Parties engaged in good faith discussions and agreed to settle any and all disputes underlying these Legal Proceedings and MediLink Therapeutics shall share with the Company a certain portion of the income and net profits (where applicable) that MediLink Therapeutics (i) has generated prior to effective date of the Settlement from the out-licensing of, and (ii) will generate after the effective date of the Settlement from the out-licensing and future sales of, in each of (i) and (ii), YL201 (B7H3), YL202 (HER3), YL211 (cMet), YL212 (DLL3), YL221 (EGFR) and YL222 (PD-L1) in MediLink Therapeutics's pipeline.

The Board is of the view that entering into the Settlement will save time and costs for the Company and is therefore in the interest of the Company. The Board is further of the view that neither the Legal Proceedings nor the Settlement had or will give rise to any material adverse impact on the financial position and operation of the Group.

Shareholders and potential investors are advised to exercise caution when dealing with the shares of the Company.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, December 16, 2025

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.